Karim Sultan Haider

Mr. Karim Sultan Haider

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
AYAksam Yassin
Aksam Yassin
AHAhmad Haider
Ahmad Haider
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
MCMonica Caliber
Monica Caliber
GDGheorghe Doros
Gheorghe Doros
WGW. Timothy Garvey
W. Timothy Garvey
OBJECTIVE Type 2 diabetes (T2D) is a public health threat. Prediabetes represents a window of opportunity for intervention to prevent T2D. Men with T2D and prediabetes often have low testosterone. Since testosterone improves glycemic control in T2D, we investigated whether testosterone therapy (TTh) in men with hypogonadism and prediabetes prevents progression to T2D. RESEARCH DESIGN AND METHODS Three hundred and sixteen men with prediabetes (defined as HbA1c 5.7–6.4%) and total testosterone levels ≤12.1 nmol/L combined with symptoms of hypogonadism were analyzed. Two hundred and twenty-nine men received parenteral testosterone undecanoate (T-group), and 87 men with hypogonadism served as untreated control subjects. Metabolic and anthropometric parameters were measured twice yearly for 8 years. RESULTS HbA1c decreased by 0.39 ± 0.03% (P < 0.0001) in the T-group and increased by 0.63 ± 0.1% (P < 0.0001) in the untreated group. In the T-group, 90% achieved normal glucose regulation (HbA1c 6.5%). TTh was also associated with significant improvements in fasting glucose, triglyceride:HDL ratio, triglyceride-glucose index, lipid accumulation product, total cholesterol, LDL, HDL, non-HDL, triglycerides, and Aging Males’ Symptoms (AMS) scale. Significant deterioration in all these parameters was seen in the untreated group. Mortality was 7.4% in the T-group and 16.1% in the untreated group (P < 0.05). The incidence of nonfatal myocardial infarction was 0.4% in the T-group and 5.7% in the untreated group (P < 0.005). CONCLUSIONS Long-term TTh completely prevents prediabetes progression to T2D in men with hypogonadism and improves glycemia, lipids, and AMS score. TTh holds tremendous potential for the large and growing population of men with prediabetes and hypogonadism.

9 February 2017 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Open access
ATAbdulmaged Traish
Abdulmaged Traish
AHAhmad Haider
Ahmad Haider
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
GDGheorghe Doros
Gheorghe Doros
FSFarid Saad
Farid Saad
In the absence of large, prospective, placebo-controlled studies of longer duration, substantial evidence regarding the safety and risk of testosterone (T) therapy (TTh) with regard to cardiovascular (CV) outcomes can only be gleaned from observational studies. To date, there are limited studies comparing the effects of long-term TTh in men with hypogonadism who were treated or remained untreated with T, for obvious reasons. We have established a registry to assess the long-term effectiveness and safety of T in men in a urological setting. Here, we sought to compare the effects of T on a host of parameters considered to contribute to CV risk in treated and untreated men with hypogonadism (control group). Observational, prospective, cumulative registry study in 656 men (age: 60.7 ± 7.2 years) with total T levels ≤12.1 nmol/L and symptoms of hypogonadism. In the treatment group, men (n = 360) received parenteral T undecanoate (TU) 1000 mg/12 weeks following an initial 6-week interval for up to 10 years. Men (n = 296) who had opted against TTh served as controls. Median follow-up in both groups was 7 years. Measurements were taken at least twice a year, and 8-year data were analyzed. Mean changes over time between the 2 groups were compared by means of a mixed-effects model for repeated measures, with a random effect for intercept and fixed effects for time, group, and their interaction. To account for baseline differences between the 2 groups, changes were adjusted for age, weight, waist circumference, fasting glucose, blood pressure, and lipids. There were 2 deaths in the T-treated group, none was related to CV events. There were 21 deaths in the untreated (control) group, 19 of which were related to CV events. The incidence of death in 10 patient-years was 0.1145 in the control group (95% confidence interval [CI]: 0.0746-0.1756; P < .000) and 0.0092 in the T-treated group (95% CI: 0.0023-0.0368; P < .000); the estimated difference between groups was 0.0804 (95% CI: 0.0189-0.3431; P < .001). The estimated reduction in mortality for the T-group was between 66% and 92%. There were also 30 nonfatal strokes and 26 nonfatal myocardial infarctions in the control group and none in the T-treated group. Long-term TU was well tolerated with excellent adherence suggesting a high level of patient satisfaction. Mortality related to CV disease was significantly reduced in the T-group.

19 June 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
AHAhmad Haider
Ahmad Haider
FSFarid Saad
Farid Saad
GDGheorghe Doros
Gheorghe Doros
MHMarkolf Hanefeld
Markolf Hanefeld
ATAbdulmaged Traish
Abdulmaged Traish
Aims Type 2 diabetes mellitus (T2DM) is a public health threat. Men with T2DM often exhibit hypogonadism. We investigated whether testosterone therapy (TTh) in men with hypogonadism and T2DM improves glycemic control, insulin sensitivity and results in remission of T2DM. Material and Methods 356 men who had total testosterone (T) ≤12.1 nmol/L (350 ng/dL) and symptoms of hypogonadism were included in the study and observed for 11 years. All patients received standard diabetes treatment. 178 men additionally received parenteral T undecanoate 1000 mg every 12 weeks following an initial 6‐week interval. 178 hypogonadal men who opted against TTh served as control group. Results Men with hypogonadism and T2DM treated with T had significant progressive and sustained reductions in fasting glucose, HbA1c and fasting insulin over the treatment period. In the control group, fasting glucose, HbA1c and fasting insulin increased. 34.3% of men treated with T achieved remission of their diabetes and 46.6% of patients achieved normal glucose regulation. 83.1% of the T‐treated group reached HbA1c target of 6.5%, 90% achieved HbA1c target of 7.0%. In contrast, no remission of diabetes or reduction in glucose or HbA1c levels were noted in the control group. There were fewer deaths, myocardial infarctions, strokes, and diabetic complications in the T‐treated group. Conclusions Long‐term TTh in men with T2DM and hypogonadism improves glycemic control and insulin resistance. Remission of diabetes occurred in one third of the patients. TTh is potentially a novel additional therapy for men with T2DM and hypogonadism.

20 February 2019 in The Aging Male
Verified
Journal Article
Closed access
FSFarid Saad
Farid Saad
MCMonica Caliber
Monica Caliber
GDGheorghe Doros
Gheorghe Doros
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
AHAhmad Haider
Ahmad Haider
Objective: The association between erectile dysfunction (ED), hypogonadism, cardiovascular disease, and type 2 diabetes is well documented, but long-term data are limited. The aim of this study is to investigate effects of long-term testosterone therapy (TTh) with testosterone undecanoate in men with hypogonadism and ED. Patients and methods: Observational, prospective registry of 805 hypogonadal men with different degrees of ED, evaluated by the International Index of Erectile Function – Erectile Function Domain. Four hundred and twelve patients underwent TTh, 393 patients served as controls, with an observation period up to 12 years. Results: TTh led to substantial and sustained reduction of ED; improvement in erectile function was significant for each successive year until year 9. This was accompanied by improvements in cardiometabolic risk factors and urinary function throughout the 12-year follow-up period. Benefits of TTh were stronger for patients with moderate/severe ED than for patients with no/minor ED. Incidence of prostate cancer, major adverse cardiovascular events, and mortality were significantly lower in men on TTh compared with untreated men. Conclusion: Long-term TTh for up to 12 years alleviates ED, improves cardiometabolic risk factors, and reduces prostate cancer. Patients must stay on TTh consistently for a long time to achieve maximum benefits of TTh.

1 January 2018 in Journal of Urology
Verified
Journal Article
Closed access
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
AHAhmad Haider
Ahmad Haider
GDGheorghe Doros
Gheorghe Doros
ATAbdulmaged Traish
Abdulmaged Traish
We investigated the effects of long-term testosterone therapy on urinary and sexual function, and quality of life in hypogonadal men. We performed an observational, prospective, cumulative registry study in 656 men with a mean ± SD age of 60.7 ± 7.2 years who had total testosterone 12.1 nmol/l or less and symptoms of hypogonadism. In the testosterone treated group 360 men received parenteral testosterone undecanoate 1,000 mg/12 weeks for up to 10 years. The 296 men who elected against testosterone therapy served as controls. From each group 82 patients were propensity matched by age, waist circumference and body mass index, resulting in 82 matched pairs of 164 men. Data were analyzed and estimated differences between the groups were adjusted for components of metabolic syndrome and quality of life. We found significant decreases in I-PSS (International Prostate Symptom Score) and post-void bladder volume (each p <0.0001) in patients receiving testosterone therapy but not in the untreated group. We recorded a decrease in AMS (Aging Males' Symptoms Scale) in the testosterone treated group but not in the untreated group (p <0.0001). We also recorded significant improvement in the IIEF-EF (International Index of Erectile Function-Erectile Function) domain in the testosterone treated group but not in the untreated group (p <0.0001). The improvement was maintained throughout followup. Long-term testosterone therapy in hypogonadal men resulted in significant improvements in urinary and sexual function, and in quality of life. In untreated hypogonadal men voiding and erectile function deteriorated with continued followup.

28 January 2020 in International Journal of Obesity
Verified
Journal Article
Open access
PDF file
FSF. Saad
F. Saad
GDG. Doros
G. Doros
Karim Sultan HaiderKarim Sultan Haider
Karim Sultan Haider
AHA. Haider
A. Haider
Background and significance: Obesity is a chronic disease, warranting long-term medical intervention. We evaluated effects of testosterone (T) therapy (Th) in men with T deficiency with normal weight, overweight and obesity on anthropometric and metabolic parameters, compared with untreated men. Methods: Hypogonadal men (n = 823) with total T ≤ 12.1 nmol/L (age: 60.6 ± 7.0 years) participated in an ongoing registry study. Among these men 474 (57.6%) were obese, 286 (34.8%) overweight and 63 (7.7%) had normal weight. T undecanoate injections were administered to 428 men and 395 remained untreated. Anthropometric and metabolic parameters were measured at least twice a year and changes adjusted for confounding factors to account for baseline differences between groups. Results: Long-term TTh in hypogonadal men, irrespective of weight at baseline, produced improvements in body weight, waist circumference (WC) and body mass index (BMI). Furthermore, TTh decreased fasting blood glucose and HbA1c and improved lipid profiles. Gradual decreases in blood pressure (systolic and diastolic) and pulse pressure occurred in men treated with T in each group. Marked reductions in mortality and major cardiovascular events were recorded in men receiving TTh. Conclusions: Our findings demonstrate that TTh produces reductions in weight, WC, and BMI. There were 77 (19.5%) deaths in the untreated groups and 23 (5.4%) in the T-groups. Based on these findings we suggest that long-term TTh in overweight and obese hypogonadal men produces progressive and sustained clinically meaningful weight loss and that TTh may contribute to reductions in mortality and incident major adverse cardiovascular events.